U.S. pharma big copyright scrapped two experimental weight loss drugs very last year—a when-daily tablet, lotiglipron, as a consequence of elevated liver enzymes in addition to a two times-day by day pill, danuglipron, as a consequence of strong side effects—but CEO Albert Bourla has mentioned the company is determined to “play and acquire”